FASN and metastatic neoplasm: Moving from the in vitro and in vivo setting to clinical samples in an effort to confirm our concept in patients, we found that Cav-1, ACC1 and FASN expression is significantly increased in metastatic disease compared to primary PCa and normal prostate further supporting that this signaling is upregulated during PCa progression.